The University of Pittsburgh proposes to continue a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer. The overall goals of the Head and Neck SPORE are to improve the prevention and treatment of head and neck cancer as well as the detection and treatment of thyroid cancer (new in this renewal). The SPORE program consists of four translational research projects, 3 focused on head and neck squamous cell carcinoma (HNSCC) and one focused on thyroid cancer, two research cores, an administrative core, a developmental research program and a career development program. The SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects jointly led by investigators in basic, applied and clinical science. The long-term goal of the Head and Neck SPORE is to conduct clinical studies based on research results from the translational research projects that will serve as the basis for improving the outcome of individuals diagnosed with head and neck cancers. The four main projects include: (1) Chemoprevention of Head and Neck Cancer; (2) Optimization of STAT3 Decoy Delivery for Head and Neck Cancer Treatment; (3) Checkpoint Receptor Targeting to Enhance Cetuximab Efficacy Against HNSCC; and (4) Molecular-Guided Risk Stratification of Thyroid Nodules and Cancer. The three cores will interact closely to assist the main research projects, developmental research projects and career development investigators in carrying out translational head and neck cancer research. The research cores include: (a) Histology/Tissue and (b) Informatics, Biostatistics and Bioinformatics. The Administrative Core will solicit feedback from the Internal and External Scientific Advisory Boards and provide scientific, regulatory and fiscal oversight for the SPORE program. The Head and Neck SPORE investigators will work together to synergistically achieve the goals of the program and will also continue to interact closely with investigators from other Head and Neck and Thyroid SPOREs at other institutions, as well as the cooperative groups, to improve the outcome of patients with cancers of the head and neck.
The goal of this application is to use a multi-disciplinary approach to improve the management and outcomes in head and neck cancers including head and neck squamous cell carcinoma and thyroid cancer. We will advance the prevention and treatment for head and neck squamous cell cancer patients by identifying new ways to prevent and treat the disease based on the biology of the individual patient's tumor and new biomarkers that predict risk and response to therapy. We will advance the management of thyroid nodules and thyroid cancer by integrating novel next generation sequencing platforms into clinical strategies.
|Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690|
|Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673|
|Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054|
|Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287|
|Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97|
|Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72|
|Lee, Yoon Se; Johnson, Daniel E; Grandis, Jennifer R (2018) An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs :1-17|
|Johnson, Daniel E; O'Keefe, Rachel A; Grandis, Jennifer R (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234-248|
|Close, David A; Camarco, Daniel P; Shan, Feng et al. (2018) The Generation of Three-Dimensional Head and Neck Cancer Models for Drug Discovery in 384-Well Ultra-Low Attachment Microplates. Methods Mol Biol 1683:355-369|
|Yang, Xi; Xia, Rui; Yue, Cuihua et al. (2018) ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Rep 23:1754-1766|
Showing the most recent 10 out of 310 publications